American Journal of Oral Medicine and Radiology

AN OBSERVATIONAL STUDY ON SAFETY AND EFFICACY OF TOPIRAMATE AS AN ADD-ON DRUG THERAPY IN SEIZURES AMONG CHILDREN OF INDIA

Challa harisha

Challa@gmail.com

Topiramate, Safety in Children, Seizures, India, Therap

Topiramate is an antiepileptic drug with anti-seizure properties around the board. It has been shown to be successful in the treatment of both partial and generalised seizures. Topiramate's effectiveness in epilepsy syndromes such as West syndrome myoclonic-astatic epilepsy and Dravet syndrome, as well as refractory status epilepticus, has been demonstrated. Topiramate may also be used as a supplement to other treatments for Lennox-Gastaut syndrome. However, there are few studies on topiramate's long-term efficacy, especially in children, that have lasted longer than 24 months. In this open-label, retrospective research, we looked at the safety and long-term efficacy of topiramate in a group of children with drugresistant epilepsy for more than 24 months. The Chi-square test was used to analyse SIS based on two parameters: the starting dose and the dose at the end of the sixth month. There is a relationship between the starting dose and the SIS location (X2=13.45, df=4, p0.05). At starting doses of 1–2 mg/kg/day and 2–3 mg/kg/day, respectively, favourable scores of 3 and 4 and unfavourable scores of 1 and 0 were maximally obtained. There is a connection between the dose at the end of the sixth month (optimum maintenance dose) and SIS position (X2=7.0, df=1, p0.05) (Table 1). At optimum doses of 2.5 to 7.5 mg/kg/day, favourable SIS scores of 3 and 4 were obtained. During the study period, none of the participants experienced any significant systemic manifestations apart from mild side effects. Two patients had hypohidrosis, which was reversed by drinking plenty of water. There were no kidney stones or metabolic acidosis in any of the participants